Primus Anabolics

QuickStart Highlights

TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid protein involved in tissue repair and regeneration. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for precise measurements with an insulin syringe in research settings.

Reconstitution: Add 3.0 ml of bacteriostatic water → ~6.67 mg/ml concentration.
Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
Easy measurement: At 6.67 mg/ml, 1 unit = 0.01 ml ≈ 66.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze the reconstituted solution.

Dosage and Reconstitution Guide

TB-500 Vial (20 mg)
Standard / gradual approach (3 ml = ~6.67 mg/ml)

Phase	Daily dose (mcg)	Units (per injection)	Volume (mL)
Weeks 1–2	500 mcg	7–8 units	0.075 mL
Weeks 3–4	600 mcg	9 units	0.09 mL
Weeks 5–8	750 mcg	11 units	0.11 mL
Weeks 9–12	1000 mcg	15 units	0.15 mL

Reminder: 1 unit ≈ 66.7 mcg
Frequency: Once daily subcutaneously. This dilution allows units to be kept in a comfortable range for precise measurement.
Approximate weekly average: ~5 mg.

Required Supplies

Plan based on an 8–16 week daily protocol.

TB-500 Vials (20 mg each) PRICE €40 per vial
8 weeks ≈ 2 vials
12 weeks ≈ 4 vials
16 weeks ≈ 5 vials
(With an average dose of ~5 mg/week → ~20 mg every 4 weeks)
Bacteriostatic water (10 ml):
- 3 ml is used per vial.
- 8 weeks (2 vials): 6 ml → 1 bottle of 10 ml
- 12 weeks (4 vials): 12 ml → 2 bottles
- 16 weeks (5 vials): 15 ml → 2 bottles

Protocol Overview

Objective: Support tissue repair, healing, and angiogenesis.
Schedule: Daily subcutaneous injections for 8–12 weeks (optional extension to 16 weeks).
Dose range: 500–1000 mcg daily (~5 mg/week average).
Reconstitution: 3.0 ml per 20 mg vial (~6.67 mg/ml).
Storage: Lyophilized frozen; reconstituted refrigerated.

Dosing Protocol

Suggested daily titration approach.
Start: 500 mcg daily; increase ~100–150 mcg every 2 weeks as tolerated.
Goal: 750–1000 mcg daily for weeks 5–12.
Frequency: Once daily (subcutaneous).
Cycle duration: 8–12 weeks; optional extension up to 16 weeks based on the research protocol.
Timing: Any consistent time daily; rotate injection sites systematically.

Storage Instructions

Proper storage preserves the quality and activity of the peptide.

Lyophilized: Store at −20 °C (−4 °F) in dry and dark conditions; minimize exposure to moisture.
Reconstituted: Refrigerate at 2-8 °C (35.6–46.4 °F); do not freeze reformulated solution as freezing can denature peptides.
Allow vials to reach room temperature before opening to reduce condensation absorption.
Use reconstituted vials within 28 days when stored with bacteriostatic water preservative.

Important Notes

Practical considerations for consistency and safety in research protocols.

Use new sterile insulin syringes for each injection; dispose of in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy.
Inject slowly; wait a few seconds before removing the needle to avoid backflow.
Document daily dose, injection site, and any observation to maintain consistency.
Regulatory note: TB‐500 is prohibited by WADA for athletic use and is not approved by the FDA for human administration.

How it works

TB-500 represents the active N-terminal fragment of thymosin beta-4, specifically the heptapeptide sequence Ac-LKKTETQ. This region is responsible for the actin-binding and cell migration properties of the complete thymosin molecule.

Preclinical studies demonstrate that TB-500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration through the up-regulation of cell motility and blood vessel formation.

Research in animal models shows enhanced collagen deposition and reduced healing time at injury sites treated with thymosin fragments. Recent metabolic studies suggest that TB-500 may act as a prodrug, being cleaved to an active pentapeptide metabolite that drives biological activity.

Potential Benefits and Side Effects

Observations from preclinical and veterinary literature.

Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration.
May indirectly reduce inflammation and fibrosis through thymosin pathways observed in animal models.
Generally well tolerated in veterinary studies; occasional mild injection site reactions (redness, tenderness) reported.
Human safety data are limited; no large-scale clinical trials have been completed for TB-500 specifically.

Lifestyle Factors

Complementary strategies for optimal research results.

Maintain an adequate protein intake to support tissue repair and regeneration processes.
Combine with appropriate physical activity; avoid overtraining during injury recovery phases.
Prioritize sleep (7–9 hours) to maximize natural recovery and repair mechanisms.
Manage stress levels through evidence-based practices to support overall healing.

Injection Technique

General subcutaneous guidance from best-practice clinical resources.

Clean vial stopper and skin with alcohol; let air dry completely.
Pinch a skin fold at the injection site; insert the needle at 45-90° into the subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically within the approved areas (abdomen, thighs, upper arms) to avoid lipohypertrophy.
Wait 5–10 seconds after injection before removing the needle to avoid medication leakage.